John E. Kao Sells 39,101 Shares of Alignment Healthcare, Inc. (NASDAQ:ALHC) Stock

Alignment Healthcare, Inc. (NASDAQ:ALHC – Get Rating) CEO John E. Kao sold 39,101 shares of the firm’s stock in a transaction that occurred on Tuesday, March 14th. The shares were sold at an average price of $6.33, for a total value of $247,509.33. Following the completion of the sale, the chief executive officer now directly owns 2,381,279 shares in the company, valued at approximately $15,073,496.07. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Alignment Healthcare Trading Down 1.2 %

Shares of ALHC opened at $6.01 on Friday. The stock has a fifty day moving average price of $10.26 and a two-hundred day moving average price of $11.81. The company has a debt-to-equity ratio of 0.67, a quick ratio of 2.37 and a current ratio of 2.37. Alignment Healthcare, Inc. has a 52-week low of $5.76 and a 52-week high of $19.17. The company has a market cap of $1.13 billion, a price-to-earnings ratio of -7.33 and a beta of 1.86.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on ALHC shares. Piper Sandler decreased their price objective on Alignment Healthcare from $19.00 to $12.00 and set an “overweight” rating on the stock in a report on Friday, March 3rd. Raymond James lowered Alignment Healthcare from an “outperform” rating to a “market perform” rating in a report on Monday, November 21st. The Goldman Sachs Group decreased their price objective on Alignment Healthcare from $21.00 to $14.00 and set a “buy” rating on the stock in a report on Friday, March 3rd. TD Cowen decreased their price objective on Alignment Healthcare from $17.00 to $10.00 and set an “outperform” rating on the stock in a report on Thursday, March 2nd. Finally, JPMorgan Chase & Co. lowered Alignment Healthcare from an “overweight” rating to a “neutral” rating and decreased their price objective for the stock from $22.00 to $12.00 in a report on Thursday, February 23rd. Three investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to data from MarketBeat, Alignment Healthcare currently has an average rating of “Moderate Buy” and an average target price of $15.64.

Hedge Funds Weigh In On Alignment Healthcare

Several institutional investors have recently bought and sold shares of the business. Price T Rowe Associates Inc. MD raised its position in Alignment Healthcare by 2.8% in the 2nd quarter. Price T Rowe Associates Inc. MD now owns 8,805,887 shares of the company’s stock valued at $100,475,000 after purchasing an additional 236,652 shares during the last quarter. T. Rowe Price Investment Management Inc. raised its position in Alignment Healthcare by 15.1% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 8,470,181 shares of the company’s stock valued at $99,610,000 after purchasing an additional 1,108,973 shares during the last quarter. Vanguard Group Inc. raised its position in shares of Alignment Healthcare by 25.1% during the third quarter. Vanguard Group Inc. now owns 8,117,393 shares of the company’s stock worth $96,111,000 after acquiring an additional 1,626,831 shares during the last quarter. Durable Capital Partners LP raised its position in shares of Alignment Healthcare by 2,079.2% during the first quarter. Durable Capital Partners LP now owns 5,908,220 shares of the company’s stock worth $66,349,000 after acquiring an additional 5,637,102 shares during the last quarter. Finally, BlackRock Inc. raised its position in shares of Alignment Healthcare by 21.8% during the third quarter. BlackRock Inc. now owns 5,698,621 shares of the company’s stock worth $67,471,000 after acquiring an additional 1,020,637 shares during the last quarter. Institutional investors own 83.49% of the company’s stock.

Alignment Healthcare Company Profile

(Get Rating)

Alignment Healthcare, Inc, a tech-enabled Medicare advantage company, operates consumer-centric health care platform. It provides customized health care in the United States to seniors and those who need it through its Medicare advantage plans. The company owns Medicare advantage plans in the states of California, North Carolina, Nevada, and Arizona.